Navigation Links
Cord blood-derived CD133+ cells improve cardiac function after myocardial infarction
Date:2/3/2010

This release is available in Chinese.

Researchers at the Pontifcia Universidade Catlica do Paran and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence. HUCB-derived EPCs could be an alternative to rescue impaired stem cell function in the sick and elderly. The results, which appear in the January 2010 issue of Experimental Biology and Medicine, show that expanded cells ex vivo exhibited increased expression of mature endothelial cells markers and formed tubule-like structures in vitro. Only the expanded cells expressed VEGF mRNA.

Cells were expanded up to 70-fold during 60 days of culture, and they retained their functional activity. A significant improvement was observed in left ventricular ejection fraction for purified and expanded cells. In summary, CD133+ cells were purified from HUCB, expanded in vitro without losing their biological activity, and both purified and expanded cells showed promising results for use in cellular cardiomyoplasty. However, further pre-clinical testing should be performed to determine whether expanded CD133+ cells have any clinical advantages over purified CD133+ cells.

Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "This study suggests that the use of human umbilical cord blood-derived purified and expanded CD133+ cells may show promise for use in cellular cardiomyoplasty. This finding needs subsequent pre-clinical testing but may prove to be very important in future treatments".


'/>"/>

Contact: Dr. Alexandra Senegaglia
alexandra.senegaglia@pucpr.br
Society for Experimental Biology and Medicine
Source:Eurekalert

Page: 1

Related biology news :

1. Cells send dirty laundry home to mom
2. Tumor suppressor p53 prevents cancer progression in cells with missegregated chromosomes
3. Disarming specialized stem cells might combat deadly ovarian cancer
4. March of Dimes awards $250,000 prize to scientist who discovered how to reprogram human cells
5. Grant to study how cells sense electric fields
6. NYSCF Fellow lead author on study that creates blood vessel cells from stem cells
7. New way to generate abundant functional blood vessel cells from human stem cells discovered
8. Update on pluripotent stem cells (hESC and iPS)
9. Excess DNA damage found in cells of patients with Friedreichs ataxia
10. Mutations in different cells cooperate to set the stage for cancer
11. Study shows that delivering stem cells improves repair of major bone injuries in rats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch ... of MDC and Charit in Berlin-Buch have gained ... and their molecular repertoire. Dr. Max Werth, Katharina ... transcription factor (grainyhead-like 2, Grhl2), which regulates the ...
... PhD student are part of a research team that ... oxygen levels in the oceans high enough to establish ... By examining ancient-ocean sediments, Kurt Konhauser, student ... last glacier to encircle Earth receded, leaving behind glacial ...
... DURHAM, N.H. A major new study that sounds ... the world,s seagrass species are faring somewhat better, says a ... the study. Fred Short, UNH research professor ... was among the 174 scientists who contributed to "The Impact ...
Cached Biology News:New insights into the development of epithelial cells 2UNH's Fred Short adds seagrass data to major conservation study 2
(Date:5/1/2015)... 2015 A new report by  ... will reach $22.4bn in 2019. That revenue forecast and ... Market Prospects 2015-2025 ,  published in March ... to provide forecasts and qualitative analyses of the antithrombotic ... consultancy in London, UK . It ...
(Date:5/1/2015)... According to a new ... Consumables), by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), ... - Analysis & Global Forecast to 2019", published ... Production Market for the forecast period of 2014 ... $2.572 Billion by 2019 from $1.425 Billion in ...
(Date:4/30/2015)... 30, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, announced ... quarter of 2015 on May 7, 2015 after the ... will also host a conference call at 4:30 p.m. ... first quarter financial results. During the conference call, material ...
(Date:4/30/2015)... MINNEAPOLIS, MN , April 30, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has commenced ... addition, BioAmber expects to grant the underwriters a 30-day ... of the shares of common stock offered in the ... and there can be no assurance as to whether ...
Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Entrepreneur Anthony ... Directors, IRVINE, Calif., Sept. 5 NeoMatrix, developer of ... to,identify breast cancer risk, announced today that the company has ... enable an expanded,market release of the HALO System, which is ...
... Sept. 5 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... the Bear Stearns 20th Annual Healthcare Conference on September,11, ... Time) at the Grand,Hyatt Hotel in New York City. ... to provide a corporate overview of the,company and its ...
... the Key Problems Faced by Insomniacs, i.e.,Sleep Onset and ... Today at 11:00 am CET (10:00 am UK,time, 5:00 ... Congress in,Australia HAMBURG, Germany and OXFORD, England, September ... the worldsleep07 congress in Cairns, Australia the,details of the ...
Cached Biology Technology:NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 2NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 3NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 4Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 2Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 4